Prescription Drugs Subject to a Risk Evaluation and Mitigation Strategy: Patient Perspectives on Risk Communication and the Value of Educational Materials.
| Publicado en: | Drug Safety Vol. 49; no. 6; pp. 667 - 676 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Jun2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=193653464&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 193653464 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 01145916 C5E jtl: Drug Safety issn: 01145916 maglogo: N pubinfo: dt: Jun2026 vid: 49 iid: 6 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 193653464 189626840 10.1007/s40264-025-01636-4 193653464 ppf: 667 ppct: 9 formats: tig: atl: Prescription Drugs Subject to a Risk Evaluation and Mitigation Strategy: Patient Perspectives on Risk Communication and the Value of Educational Materials. aug: au: Chimonas, Susan Cosenza, Carol Kesselheim, Aaron S. Toyserkani, Gita A. Oswell, Kate Heinrich LaCivita, Cynthia Dal Pan, Gerald J. Sarpatwari, Ameet affil: https://ror.org/02yrq0923 Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, NY, USA sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|